Stock 688266 SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Equities

688266

CNE100003RP1

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
55.3 CNY -0.14% Intraday chart for Suzhou Zelgen Biopharmaceuticals Co.,Ltd. +0.36% +4.46%
19/04 Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
12/04 Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials
MT
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Zelgen Biopharmaceuticals Grants Yuanda Life Unit Marketing Rights for Recombinant Human Thrombin
MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zelgen Biopharma’s Phase III Trial of Thyroid Cancer Treatment Yields Positive Results
MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(XSSC:688266) added to S&P Global BMI Index
CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Zelgen Biopharmaceuticals Gets Nod for China Clinical Trial of Solid Tumor Drug
MT
Apeloa Pharma Forms Strategic Drug Alliance With Zelgen Biopharma
MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that it has received CNY 1.45529 billion in funding
CI
Zelgen Biopharma Gets Nod for Clinical Trials of Tumor Drug
MT
Zelgen Biopharmaceuticals Wins FDA Nod to Trial Lung Cancer Drug
MT
Zelgen Biopharmaceuticals Certified as High-Tech Enterprise in China
MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Zelgen Biopharma Wins Nod to Launch Clinical Trial of Tumor Treatment
MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(SHSE:688266) dropped from Shanghai Stock Exchange Health Care Sector Index
CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688266 Stock
  4. News Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW